HeartBeam (BEAT)
(Delayed Data from NSDQ)
$2.03 USD
-0.09 (-4.25%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $2.03 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.03 USD
-0.09 (-4.25%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $2.03 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Philips (PHG) Expands Portfolio With BioTelemetry Acquisition
by Zacks Equity Research
Philips (PHG) enters into a deal to acquire BioTelemetry, which drives the expansion of its cardiac care portfolio and fuels customer acquisition.
BioTelemetry (BEAT) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
BioTelemetry (BEAT) delivered earnings and revenue surprises of 15.38% and 7.96%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
BioTelemetry (BEAT) Looks Good: Stock Adds 7.7% in Session
by Zacks Equity Research
BioTelemetry (BEAT) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
BioTelemetry (BEAT) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
BioTelemetry (BEAT) delivered earnings and revenue surprises of 191.67% and 15.34%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for BioTelemetry (BEAT) This Earnings Season?
by Zacks Equity Research
BioTelemetry (BEAT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
BioTelemetry (BEAT) to Report Q1 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
BioTelemetry (BEAT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioTelemetry (BEAT) Q4 Earnings Meet Estimates
by Zacks Equity Research
BioTelemetry (BEAT) delivered earnings and revenue surprises of 0.00% and 1.53%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
BioTelemetry (BEAT) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
BioTelemetry (BEAT) delivered earnings and revenue surprises of 4.00% and 0.28%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
BioTelemetry (BEAT) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
BioTelemetry (BEAT) delivered earnings and revenue surprises of 17.78% and 0.65%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate BioTelemetry (BEAT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
BioTelemetry (BEAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioTelemetry (BEAT) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
BioTelemetry's (BEAT) strong second-quarter 2019 expectations are indicative of solid results.
Analysts Estimate BioTelemetry (BEAT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
BioTelemetry (BEAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioTelemetry (BEAT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
BioTelemetry (BEAT) closed the most recent trading day at $47.69, moving +1.6% from the previous trading session.
BioTelemetry (BEAT) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Products like MCT and Ware Holter are likely to aid BioTelemetry (BEAT) in Q1.
Bull of the Day: BioTelemetry (BEAT)
by Kevin Cook
Medical research partner to Apple in large cardiac monitoring study, this serial earnings surpriser just went on sale
Top Stock Picks for the Week of Apr 22, 2019
by Panel Of Zacks Experts
Tracey Ryniec and Kevin Cook look at two highly rated stocks.
BioTelemetry (BEAT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, BioTelemetry (BEAT) closed at $55.13, marking a +0.35% move from the previous day.
BioTelemetry (BEAT) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
BioTelemetry (BEAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teladoc's Partnership to Form Pediatric Telehealth Platform
by Zacks Equity Research
Teladoc (TDOC) teams up with Cincinnati Children's Hospital Medical Center to launch consumer pediatric telehealth platform.
Has BioTelemetry (BEAT) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (BEAT) Outperforming Other Medical Stocks This Year?
BioTelemetry (BEAT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, BioTelemetry (BEAT) closed at $60.03, marking a -0.94% move from the previous day.
BioTelemetry (BEAT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, BioTelemetry (BEAT) closed at $62.11, marking a +0.57% move from the previous day.
BioTelemetry (BEAT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
BioTelemetry (BEAT) closed the most recent trading day at $68.46, moving +0.87% from the previous trading session.
Teladoc to Acquire MedecinDirect, Expand Overseas Business
by Zacks Equity Research
Teladoc's (TDOC) acquisition of MedecinDirect will aid it in enhancing presence in expanding virtual care market in France.
Is BioTelemetry (BEAT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (BEAT) Outperforming Other Medical Stocks This Year?